SCHEMBL252244

SCHEMBL252244

CCCc1nc2ccccc2c(F)c1C(C)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
NPSR1 Q6W5P4 1/20 0.38
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ELANE P08246 1/20 0.38
TSHR P16473 1/20 0.38
PTK2B Q14289 1/20 0.38
GAA P10253 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
HTT P42858 1/20 0.37
LMNA P02545 1/20 0.36
USP2 O75604 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL252243 1.00 PDE4A (0.39) PDE4APDE4BPDE4CPDE4DNPSR1
SCHEMBL252645 0.74 TDP1 (0.34) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL252646 0.74 TDP1 (0.34) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL6521318 0.71 MET (0.52)
SCHEMBL29869959 0.71 MET (0.52)
SCHEMBL253949 0.65 TDP1 (0.40) GAAKDM4EALDH1A1HPGDTDP1
SCHEMBL21362625 0.65 USP2 (0.38) PDE4APDE4BPDE4CPDE4DNPSR1
SCHEMBL3414301 0.65 TDP1 (0.34) MAPTSMN1; SMN2GAAALDH1A1TDP1
SCHEMBL14860189 0.65 TDP1 (0.34) MAPTSMN1; SMN2GAAALDH1A1TDP1
SCHEMBL14859955 0.65 TDP1 (0.34) MAPTSMN1; SMN2GAAALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588469-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
WO-2012003271-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed